Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of H ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...